Evidence map›Paper›PMID 40670372›Full record

ArticleNPJ vaccines2025

Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia.

Lucy Deng, Amanda Van Eldik, Megan O'Moore, Jim Buttery, Abigail Cheung, Nicholas Cox, Carla Drake-Brockman, Nathan Dwyer, Paul Effler, Michael Gold and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Global vaccine development.Nature medicine · 2026
    Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Lucy DengNational Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia. lucy.deng@health.nsw.gov.au.
Amanda Van EldikNational Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia.
Megan O'MooreTherapeutic Goods Administration, Department of Health, Disability and Ageing, Canberra, ACT, Australia.
Jim ButteryMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Abigail CheungWomen's and Children's Health Network, Adelaide, South Australia, Australia.
Nicholas CoxWestern Health, Victoria, Australia.
Carla Drake-BrockmanPerth Children's Hospital, Nedlands, Western Australia, Australia.
Nathan DwyerRoyal Hobart Hospital, Hobart, Tasmania, Australia.
Paul EfflerWestern Australia Department of Health, Perth, Western Australia, Australia.
Michael GoldWomen's and Children's Health Network, Adelaide, South Australia, Australia.
Pravin HissariaSchool of Medicine, Adelaide University, Adelaide, South Australia, Australia.
Andrew KellyWomen's and Children's Health Network, Adelaide, South Australia, Australia.
Sarah KhanlariNew South Wales Ministry of Health, St Leonards, NSW, Australia.
Claire LarterTherapeutic Goods Administration, Department of Health, Disability and Ageing, Canberra, ACT, Australia.
Shannon MelodyPublic Health Services, Department of Health Tasmania, Hobart, Tasmania, Australia.
Michael NissenQueensland Adult Specialist Immunisation Service, The Prince Charles Hospital, Chermside, Queensland, Australia.
Rajesh PuranikRoyal Prince Alfred Hospital, Camperdown, NSW, Australia.
James RankinFiona Stanley Hospital, Murdoch, Western Australia, Australia.
Sally SingletonAustralian Capital Territory Health Directorate, Canberra, ACT, Australia.
Liza ThomasThe University of Sydney's Westmead Clinical School, Westmead, NSW, Australia.
Sudhir WahiPrincess Alexandra Hospital, Brisbane, Queensland, Australia.
Gavin WheatonWomen's and Children's Health Network, Adelaide, South Australia, Australia.
Dominica ZentnerRoyal Melbourne Hospital Clinical School, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia.
Clara K ChowWestmead Hospital, Westmead, NSW, Australia.
Nicholas WoodNational Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccinations remains an important but undefined public health concern. We conducted prospective follow-up of individuals with either confirmed or probable myocarditis following monovalent Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccination between 21 April 2021 and 5 July 2022 in Australia. Of 256 individuals who consented to follow up, mostly males following a second dose, 60% (133/221) had ongoing symptoms at 3-6 months and 35% (81/231) at 12-18 months. Self-reported ongoing exercise restrictions, medication requirements, and hospital re-presentations were associated with ongoing symptoms, as was a lower self-reported health status and quality of life. Clinical severity remained mild, with low hospitalisation rates and no deaths in the follow-up period and health-related quality of life improved over time. These findings support ongoing use of mRNA COVID-19 vaccines in at-risk individuals to prevent disease caused by SARS-CoV-2 infection.

Identifiers

PMID40670372
PMCPMC12267834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.